ANNX vs. BMEA, HRTX, KRRO, MRSN, LXRX, NGNE, CRBP, ESPR, PEPG, and RVNC
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Biomea Fusion (BMEA), Heron Therapeutics (HRTX), Korro Bio (KRRO), Mersana Therapeutics (MRSN), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
Biomea Fusion has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
96.7% of Biomea Fusion shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by insiders. Comparatively, 19.1% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biomea Fusion presently has a consensus price target of $53.25, indicating a potential upside of 381.03%. Annexon has a consensus price target of $14.43, indicating a potential upside of 196.27%. Given Annexon's higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Annexon.
In the previous week, Biomea Fusion had 7 more articles in the media than Annexon. MarketBeat recorded 9 mentions for Biomea Fusion and 2 mentions for Annexon. Annexon's average media sentiment score of 0.18 beat Biomea Fusion's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.
Annexon received 9 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 71.93% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Biomea Fusion's return on equity of -66.54% beat Annexon's return on equity.
Summary
Annexon beats Biomea Fusion on 8 of the 14 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
